Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business

You may also be interested in...



Takeda’s Strategic Run Up To Nycomed

With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.

Takeda’s Vaccine Business Aims High, Led By Former Gates Foundation Vaccine Director

Established in January 2012 on the foundation of Takeda’s long-standing domestic pediatric vaccine business, the new initiative will be global in scale, building on the territorial gains from the Nycomed acquisition, and led by a seasoned player.

Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?

TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies

Related Content

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel